DnB Asset Management AS Sells 759 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

DnB Asset Management AS decreased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 33.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,537 shares of the company’s stock after selling 759 shares during the quarter. DnB Asset Management AS’s holdings in Krystal Biotech were worth $241,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new position in Krystal Biotech during the fourth quarter worth $34,391,000. State Street Corp increased its stake in shares of Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Krystal Biotech in the 4th quarter valued at about $15,989,000. Franklin Resources Inc. lifted its stake in Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after purchasing an additional 62,178 shares during the last quarter. Finally, TimesSquare Capital Management LLC grew its holdings in Krystal Biotech by 39.1% during the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company’s stock worth $24,888,000 after purchasing an additional 44,646 shares during the period. Institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on KRYS. Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Citigroup increased their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $220.00.

Krystal Biotech Stock Up 3.7 %

Shares of NASDAQ:KRYS opened at $181.00 on Thursday. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34. The company’s 50 day moving average price is $172.47 and its two-hundred day moving average price is $173.31. The firm has a market cap of $5.21 billion, a PE ratio of 60.54 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s revenue was up 116.4% on a year-over-year basis. During the same quarter last year, the company earned $0.30 EPS. On average, research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Buying and Selling

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).